- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT01664273
Gene Electrotransfer to Muscle With Plasmid AMEP in Patients With Disseminated Cancer
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Cohorts of 3 patients will be treated with increasing doses of plasmid AMEP. Up to 12 patients will be treated.
Treatment procedure: Local anesthetic is applied to m. quadriceps femoris (thigh muscle) and the skin. An incision of the skin is performed followed by dissection until the muscle is exposed. The surgical procedure is performed by plastic surgeons.
Plasmid AMEP is injected intramuscularly and immediately followed by application of electric pulses via a needle electrode inserted into the muscle. A combination of one high voltage pulse (700V/cm, 100 µs) followed by one low voltage pulse (80 V/cm, 400 ms) will be applied. The wound is sutured and a dressing is applied. Treatment procedure is estimated to 30 minutes.
All patients are hospitalized for 24 hours after treatment for the purpose of evaluation of vital signs, physical examination, AE and SAE recording and pharmacokinetics sampling (blood and urine).
Blood biochemistry including LDH and CK is taken 24 hours post treatment. ECG will be taken before and after treatment. Patients score discomfort or pain from treated area using VAS.
Type d'étude
Inscription (Réel)
Phase
- La phase 1
Contacts et emplacements
Lieux d'étude
-
-
-
Herlev, Danemark, 2730
- Depart. of Oncology, Copenhagen Universtiy Hospital Herlev
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Age > 18 years.
- Performance status < 1 (ECOG).
- Histologically confirmed malignant tumor (solid tumor) of any histology,
- Metastatic disease. Patients with asymptomatic brain metastases are eligible.
- Patient should have been offered standard treatment. Patient is eligible if no standard treatment is available or if the patient does not wish to receive standard treatment.
- Life expectancy ≥ 3 months.
- Measurable disease defined as at least one measurable lesion according to RECIST 1.1
- Patient should have adequate organ function:
- Adequate bone marrow function: Neutrophil count ≥ 1.0 x 109/l (≤ grade 2 CTCAE 4.0); Platelet count ≥ 75 x 109/l (< grade 2 CTCAE 4.0); Hemoglobin ≥ 6,0 mmol/l.
- Liver: ALAT or ASAT < 3 ULN (< grade 2 CTCAE 4.0); Bilirubin ≤ 1,5 ULN (< grade 2 CTCAE 4.0); APTT within normal range; INR ≤ 1,2 (< grade 1 CTCAE 4.0)
- Kidney: Plasma creatinin ≤ 1.5 ULN (< grade 2 CTCAE 4.0)
- At least 4 weeks since any anti-cancer treatment.
- Men and women of reproductive age must use effective contraception during the study and at least 6 months after administration of plasmid AMEP.
- Patient should be able to understand the participant information and able to comply with protocol requirements and scheduled visits.
- Signed informed consent.
Exclusion Criteria:
- Allergy to the anaesthetic used.
- Clinical signs of active infection.
- Implanted pacemaker, defibrillator or any other implanted electronic device.
- Participation in other clinical trials involving experimental drugs or participation in a clinical trial within 4 weeks before initiation of study treatment.
- AMI (acute myocardial infarction), stroke or acute ischemic event within the last 6 months.
- Severe atherosclerosis, significant cardiovascular disease (NYHA III or IV) or significant arrhythmias.
- Systolic blood pressure above 180 mm Hg and/or diastolic blood pressure above 110 mm Hg. If BP >180/110 mm Hg medical correction is allowed and the patient can be included when BP < 180/110 mm Hg.
- Pregnancy and lactation.
- Clinically significant coagulopathy.
- Treatment with anticoagulant drugs.
- Other disorders which the investigator finds incompatible with participation in the study.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Safety of the trial treatment
Délai: From treatment to last follow up, planned 8 weeks.
|
Safety is evaluated by registration of adverse events (Adverse Events and Serious Adverse Events) using the CTCAE criteria version 4.0.
Patients are seen in the out patient clinic once a week during the first month after treatment (at day 8, day 15, day 22, day 29) and 8 weeks after treatment.
If no progression of the disease at 8 weeks, patients are seen at 12 weeks and then every three months until disease progression or death.
|
From treatment to last follow up, planned 8 weeks.
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Efficacy of the trial treatment
Délai: PET/CT scan 4 weeks, 8 weeks and 12 weeks after trial treatment.
|
PET/CT scan will be evaluated using RECIST 1.1 (CT) and PERCIST (PET)
|
PET/CT scan 4 weeks, 8 weeks and 12 weeks after trial treatment.
|
Pharmacokinetics
Délai: Pre-dose, 2, 6 and 24 hours after dose, day 8, 15, 22, 29 and 8 weeks after treatment.
|
Measurements of plasma and urine plasmid AMEP concentrations.
Measurements of plasma and urine protein AMEP concentrations
|
Pre-dose, 2, 6 and 24 hours after dose, day 8, 15, 22, 29 and 8 weeks after treatment.
|
Discomfort associated with the treatment procedure
Délai: Scoring 'immediately after treatment', '30 min after treatment' '6 hours after treatment' and 'pain in the past 24 hours', and day 8.
|
The patient completes VAS (Visual Analogue Scale) scores pain related to the treatment area at abovementioned time points.
|
Scoring 'immediately after treatment', '30 min after treatment' '6 hours after treatment' and 'pain in the past 24 hours', and day 8.
|
Safety
Délai: Day after treatment and 14 days after treatment
|
MR scan of treated region (thigh muscle) in order to assess potential intramuscular edema or hematoma
|
Day after treatment and 14 days after treatment
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Julie Gehl, MD DMSci, Department of Oncology, Copenhagen University Hospital Herlev
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Anticipé)
Achèvement de l'étude (Anticipé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- AA 1201
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Plasmid AMEP
-
Lisa H. Butterfield, Ph.D.National Cancer Institute (NCI)RésiliéCarcinome hépatocellulaire | Cancer du foie | Cancer du foie | Hépatome | Cancer hépatocellulaire | Cancer du foie | Carcinome des cellules hépatiques | Cancer, hépatocellulaire | Cancer du foie, adulte | Carcinome des cellules hépatiques, adulte | Cancer du foie | Tumeurs, Foie | Tumeurs hépatiques | Tumeurs hépatiquesÉtats-Unis
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)ComplétéCarcinome récurrent des trompes de Fallope | Carcinome ovarien récurrent | Carcinome péritonéal primitif récurrent | Cystadénocarcinome à cellules claires de l'ovaire | Adénocarcinome endométrioïde ovarien | Carcinome séromucineux de l'ovaire | Cystadénocarcinome séreux ovarien | Carcinome indifférencié...États-Unis